Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours

Medley, L., Morel, A. N., Farrugia, D., Reed, N., Hayward, N., Davies, J. M., Kirichek, O., Thakker, R.V. and Talbot, D. C. (2011) Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. British Journal of Cancer, 104(7), pp. 1067-1070. (doi: 10.1038/bjc.2011.76)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1038/bjc.2011.76

Abstract

BACKGROUND: This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs). METHODS: Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1-14 of 3-week cycles. RESULTS: Treatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue. CONCLUSION: The study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management of NETs. British Journal of Cancer (2011) 104, 1067-1070. doi: 10.1038/bjc.2011.76 www.bjcancer.com Published online 8 March 2011

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Reed, Dr Nicholas
Authors: Medley, L., Morel, A. N., Farrugia, D., Reed, N., Hayward, N., Davies, J. M., Kirichek, O., Thakker, R.V., and Talbot, D. C.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:British Journal of Cancer
ISSN:0007-0920

University Staff: Request a correction | Enlighten Editors: Update this record